The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors

American Journal of Hematology

Volumn 90, Issue 6, 2015, Pages E117-E121

  Busca, Alessandro ^a   Passera, Roberto ^a   Pini, Massimo ^b   Zallio, Francesco ^b   Dellacasa, Chiara ^a   Audisio, Ernesta ^a   Giaccone, Luisa ^a   Maffini, Enrico ^a   Costa, Cristina ^a   Cavallo, Rossana ^a   Bruno, Benedetto ^a  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b AO Nazionale Alessandria   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR; THYMOCYTE ANTIBODY; VALGANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNRELATED DONORS; VIRUS REACTIVATION; VIRUS REPLICATION; CYTOMEGALOVIRUS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PHYSIOLOGY; SURVIVAL RATE; VIROLOGY; VIRUS ACTIVATION;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SURVIVAL RATE; UNRELATED DONORS; VIRUS ACTIVATION;

EID: 84929505233     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23998     Document Type: Article

References (24)

1. Lönnqvist B, Ringdèn O, Ljungman P, et al. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol 1986;63:671.
2. Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: Evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011;118:1402-1412.
3. Green ML, Leisenring WM, Kie H, et al. CMV reactivation after allogeneic HCT and relapse risk: Evidence for early protection in acute myeloid leukemia. Blood 2013;122:1316-1324.
4. Ito S, Pophali P, CO W, et al. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant 2013;48:1313-1316.
5. Mariotti J, Maura F, Spina F, et al. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014;20:881-903.
6. Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant 2014;20:46-52.
7. Thomson KJ, Mackinnon S, Peggs KS. CMV-specific cellular therapy for acute myeloid leukemia? Blood 2012;119:1088-1090.
8. Lavagna A, Bergallo M, Daperno M, et al. Infliximab and the risk of latent viruses reactivation in active crhon disease. Inflamm Bowel Dis 2007;13:896-902.
9. Costa C, Balloco C, Sidoti F, et al. Evaluation of CMV-specific cellular immune response by EliSPOT assay in kidney transplant patients. J Clin Virol 2014;61:523-528.
10. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European leukemia net AML working party consensus statement an allogenic HSCT for patients with AML in remission: On integrated-risk adapted approach. Nat Rev Clin Oncol 2012;9:579-590.
11. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304.
12. Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956.
13. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 1999;94:496-509.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958;53:457-481.
16. Jacobsen N, Badsberg JH, Lonqvist B, et al. Graft-versus-leukaemia activity associated with cytomegalovirus antibody positive bone marrow donors in acute myeloid leukemia. Lancet 1987;456-457.
17. Jang JE, Kim SJ, Cheong J-W, et al. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann Hematol 2015;94:275-282.
18. Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013;31:1530-1538.
19. Knight A, Madrigal AJ, Grace S, et al. The role of Vdelta2-negative gammadelta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 2010;116:2164-2172.
20. Scotet E, Martinez LO, Grant E, et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein a-I. Immunity 2005;22:71-80.
21. Scheper W, van Dorp S, Kersting S, et al. γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 2013;27:1328-1338.
22. Schmidt-Hieber M, Schwarck S, Stroux A, et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: The important impact of in vivo T cell depletion. Int J Hematol 2010;91:877-885.
23. Foley B, Cooley S, Verneris MR, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012;119:2665-2674.
24. Barrett AJ. CMV: When bad viruses turn good. Blood 2011;118:1193-1194.